Nanomedicines - Tiny particles and big challenges

Marques, Margareth; Choo, Qiuyi; Ashtikar, Mukul; Rocha, Thais; Bremer‐Hoffmann, Susanne; Wacker, Matthias G.

doi:10.1016/j.addr.2019.06.003

Cited by 83 publications

(63 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are plenty of reports of successful attempts of biofilm treatment by AuNPs and AgNPs at preclinical phases. Despite their success in preclinical testing, the antimicrobial nanotherapeutic approaches still face a great hurdle of clinical testing [ 94 ]. The important caveat in finding new antimicrobial compounds is biosafety and biocompatibility.…”

Section: Conclusion and Perspectivementioning

confidence: 99%

Interactions of Gold and Silver Nanoparticles with Bacterial Biofilms: Molecular Interactions behind Inhibition and Resistance

Joshi

Singh

Mijaković

2020

IJMS

166

113

View full text Add to dashboard Cite

Many bacteria have the capability to form a three-dimensional, strongly adherent network called ‘biofilm’. Biofilms provide adherence, resourcing nutrients and offer protection to bacterial cells. They are involved in pathogenesis, disease progression and resistance to almost all classical antibiotics. The need for new antimicrobial therapies has led to exploring applications of gold and silver nanoparticles against bacterial biofilms. These nanoparticles and their respective ions exert antimicrobial action by damaging the biofilm structure, biofilm components and hampering bacterial metabolism via various mechanisms. While exerting the antimicrobial activity, these nanoparticles approach the biofilm, penetrate it, migrate internally and interact with key components of biofilm such as polysaccharides, proteins, nucleic acids and lipids via electrostatic, hydrophobic, hydrogen-bonding, Van der Waals and ionic interactions. Few bacterial biofilms also show resistance to these nanoparticles through similar interactions. The nature of these interactions and overall antimicrobial effect depend on the physicochemical properties of biofilm and nanoparticles. Hence, study of these interactions and participating molecular players is of prime importance, with which one can modulate properties of nanoparticles to get maximal antibacterial effects against a wide spectrum of bacterial pathogens. This article provides a comprehensive review of research specifically directed to understand the molecular interactions of gold and silver nanoparticles with various bacterial biofilms.

show abstract

Section: Conclusion and Perspectivementioning

confidence: 99%

Interactions of Gold and Silver Nanoparticles with Bacterial Biofilms: Molecular Interactions behind Inhibition and Resistance

Joshi

Singh

Mijaković

2020

IJMS

166

113

View full text Add to dashboard Cite

show abstract

“…The production of the drug becomes more challenging with the inclusion of multiple targeting components, addition of surface modification with ligands and/or coatings, or by encapsulation of more than one therapeutic agent. The multistep production process not only makes the quality control and quality assurance evaluation of the products difficult, but it also poses inevitable problems for following Good Manufacturing Practices in largescale production [64,65].…”

Section: Non-specified Manufacturing Guidelinesmentioning

confidence: 99%

An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market

et al. 2020

View full text Add to dashboard Cite

The advent of the twenty-first century marked a paradigm shift in the healthcare sector with coming of automated, sensitive, targeted medicines and technologies having diagnostic, prophylactic and therapeutic effects. Nanomedicines also attained wide acclamation in their initial years, but the transformation from being the proof of concept to successfully marketed products seems very daunting. Although the reason for this may be attributed to slow but incremental character of many present-day technologies, the review asserts that there are other significant facets that may purvey a thorough explanation of this scenario. The article elaborately discusses the hurdles hindering clinical translation of nanomedicines including scale-up challenges, in vitro in vivo cascade of toxicology assays, along with unrefined manufacturing guidelines, inadequate regulatory approvals, competitive conventional market, etc., leading to hesitant investments by pharmaceutical giants. The paper also explores the economic viability of nanobiotechnology sector through an empirical investigation of the revenue data of various pharmaceutical industries manufacturing nano-based drugs, which indicates minor commercial importance of these medicines. We also laid down a comprehensive set of recommendations to smoothen the translational pathway of nanomedicines from an idea to reality, efface the consumer distrust and push boundaries for development and launching of safe, efficient and commercially successful products. Keywords Nanobiotechnology. Nanomedicines. Nanopharmaceuticals. Clinical translation For the past few decades, nanobiotechnology has been proclaimed as the 'revolution in making' with the potential Highlights • Nanomedicines are extensively researched for their highly claimed efficacy, biocompatibility and unexplored potential. • The clinical translation of nanopharmaceuticals from laboratory to market undergoes many challenges on their pathway. • Major hurdles restricting the market dominance of nanomedicines includes limited investments by pharmaceutical, toxicological assays, biocompatibility risks, scale-up issues, regulatory limitations, etc. • Comparative analysis of annual reports of big pharmaceutical companies for gross sales and revenue contributed by nanomedicines. Recommendations to improve the research, development, manufacture and sales of nanopharmaceuticals.

show abstract

“…This opened the door to a range of medical applications, including transformative technologies for point of care monitoring and diagnostics devices. It's thus a timely occasion to review the successes of nanoparticles and sensors tailored to serve highly specific functions, from medical applications [2][3][4][5][6] to sensing the environment [7][8][9][10][11][12], as well as to ask where and when caution is warranted [13][14][15][16][17][18][19][20][21][22][23].…”

Section: Assessing the Progress Madementioning

confidence: 99%

“…In Switzerland, for example, the Schweizerische Unfallversicherungsanstalt (SUVA) recognized asbestosis as profession-related disease in 1939, yet the usage of asbestos was banned in Switzerland only in 1995. This illustrates that major investments into studying the health risks of nanoparticles and sensors that enter the environment or the human body in high quantities, most prominently via the food chain or the air are urgently needed [14,15,23].…”

Section: A Thorough Assessment Of Potential Health Risks Is Urgently mentioning

confidence: 99%

Nanosensors and particles: a technology frontier with pitfalls

Vogel

2019

J Nanobiotechnol

View full text Add to dashboard Cite

As we are approaching 20 years after the US National Nanotechnology Initiative has been announced, whereby most of that funding was spend to engineer, characterize and bring nanoparticles and nanosensors to the market, it is timely to assess the progress made. Beyond revolutionizing nonmedical applications, including construction materials and the food industry, as well as in vitro medical diagnostics, the progress in bringing them into the clinic has been far slower than expected. Even though most of the advances in nanosensor and nanoparticle research and development have been paid for by disease-oriented funding agencies, much of the gained knowledge can now be applied to treat or learn more about our environment, including water, soil, microbes and plants. As the amount of engineered nanoparticles that enter our environment is currently exponentially increasing, much tighter attention needs to be paid to assessing their health risk. This is urgent as the asbestos story told us important lessons how financial interests arising from a rapid build up of a flourishing industry has blocked and is still preventing a worldwide ban on asbestos, nearly 100 years after the first health risks were reported.

show abstract

Nanomedicines - Tiny particles and big challenges

Cited by 83 publications

References 149 publications

Interactions of Gold and Silver Nanoparticles with Bacterial Biofilms: Molecular Interactions behind Inhibition and Resistance

Interactions of Gold and Silver Nanoparticles with Bacterial Biofilms: Molecular Interactions behind Inhibition and Resistance

An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market

Nanosensors and particles: a technology frontier with pitfalls

Contact Info

Product

Resources

About